EP2661278
TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
4.1.2012EP published:
19.6.2019EP application number:
12732263.4
EPO information:
European Patent Register
Max expiry date:
3.1.2032
Title:
TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY (CDC) ANTIBODIES GENERATED BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS, FOR USE IN THE TREATMENT OF CANCER
Timeline
Today
4.1.2012EP application
19.6.2019EP Publication
Owner
Name:
SillaJen Biotherapeutics, Inc.Address:
450 Sansome Street, Suite 650, 94111, San Francisco, CA, US
Name:
Sillajen, Inc.Address:
307 Hyowon IC Building Pusan National University San 30, 609-735, Busan, KR
Inventor
Name:
KIRN, DavidAddress:
Mill ValleyCalifornia, US
Name:
BELL, JohnAddress:
OttawaOntario K1H 8L6, CA
Name:
BREITBACH, CarolineAddress:
San FranciscoCalifornia, US
Name:
MOON, AnneAddress:
San FranciscoCalifornia, US
Name:
HWANG, Tae-HoAddress:
Busan, KR
Name:
LEE, Yu KyoungAddress:
Busan, KR
Name:
KIM, Mi-kyungAddress:
Busan, KR
Priority
Number:
201161429622 PDate:
4.1.2011Country:
US
Classification
Categories:
A61K 35/768, A61K 35/76, C07K 16/30, A61K 39/395, A61P 35/00, A61K 39/12